[
  {
    "ts": null,
    "headline": "Abbott Laboratories stock underperforms Wednesday when compared to competitors",
    "summary": "Abbott Laboratories stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=f638a63655cbfca3dd24ba483671febf51616b14db035daff0a8d6e4abc8a520",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755102720,
      "headline": "Abbott Laboratories stock underperforms Wednesday when compared to competitors",
      "id": 136352970,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Abbott Laboratories stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=f638a63655cbfca3dd24ba483671febf51616b14db035daff0a8d6e4abc8a520"
    }
  },
  {
    "ts": null,
    "headline": "Saudi Arabia Clinical Chemistry Analyzer Market Forecast and Company Analysis Report 2025-2033 Featuring Thermo Fisher Scientific, Abbott, Siemens, Danaher, J&J, Sysmex ADR, HORIBA, Hitachi",
    "summary": "The Saudi Arabia Clinical Chemistry Analyzer Market is set to reach US$ 249.11 million by 2033, growing from US$ 170.98 million in 2024 at a 4.27% CAGR. Market growth is fueled by government healthcare investments under Vision 2030, alongside rising chronic diseases and an aging population demanding precise diagnostics. Technological advancements in automation, AI integration, and point-of-care testing further enhance accessibility, especially in underserved areas. With increasing involvement fr",
    "url": "https://finnhub.io/api/news?id=16acc0a5636a83fdea177fe0b8c82b7fce275e73343404759f50859aad796588",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755094260,
      "headline": "Saudi Arabia Clinical Chemistry Analyzer Market Forecast and Company Analysis Report 2025-2033 Featuring Thermo Fisher Scientific, Abbott, Siemens, Danaher, J&J, Sysmex ADR, HORIBA, Hitachi",
      "id": 136339446,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The Saudi Arabia Clinical Chemistry Analyzer Market is set to reach US$ 249.11 million by 2033, growing from US$ 170.98 million in 2024 at a 4.27% CAGR. Market growth is fueled by government healthcare investments under Vision 2030, alongside rising chronic diseases and an aging population demanding precise diagnostics. Technological advancements in automation, AI integration, and point-of-care testing further enhance accessibility, especially in underserved areas. With increasing involvement fr",
      "url": "https://finnhub.io/api/news?id=16acc0a5636a83fdea177fe0b8c82b7fce275e73343404759f50859aad796588"
    }
  },
  {
    "ts": null,
    "headline": "Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk",
    "summary": "The Saudi Arabia Blood Glucose Device Market is anticipated to grow from US$ 143.96 million in 2024 to US$ 259.8 million by 2033, exhibiting a CAGR of 6.78% from 2025-2033. This growth is fueled by rising diabetes incidence, increased health awareness, and government initiatives supporting early diagnosis and self-monitoring. Advances in Continuous Glucose Monitoring (CGM) systems and user-friendly glucometers enhance patient compliance. Key market players include Abbott Laboratories, Medtronic,",
    "url": "https://finnhub.io/api/news?id=92d62bc86b044c77c5956389ca3b7d2e7db0d76d63805376bc0ed89cee489570",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755091260,
      "headline": "Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk",
      "id": 136328297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The Saudi Arabia Blood Glucose Device Market is anticipated to grow from US$ 143.96 million in 2024 to US$ 259.8 million by 2033, exhibiting a CAGR of 6.78% from 2025-2033. This growth is fueled by rising diabetes incidence, increased health awareness, and government initiatives supporting early diagnosis and self-monitoring. Advances in Continuous Glucose Monitoring (CGM) systems and user-friendly glucometers enhance patient compliance. Key market players include Abbott Laboratories, Medtronic,",
      "url": "https://finnhub.io/api/news?id=92d62bc86b044c77c5956389ca3b7d2e7db0d76d63805376bc0ed89cee489570"
    }
  },
  {
    "ts": null,
    "headline": "MDT Stock Trades Cheaper Than Peers Ahead of Q1 Earnings: Time to Buy?",
    "summary": "Medtronic trades at a notable discount to peers as Q1 earnings loom, but rising costs and tariffs could test its resilience.",
    "url": "https://finnhub.io/api/news?id=a86cc3c3a5ffd984f6a96a10c9806102346e90b237e2f764e53648ad79925614",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755088620,
      "headline": "MDT Stock Trades Cheaper Than Peers Ahead of Q1 Earnings: Time to Buy?",
      "id": 136339597,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Medtronic trades at a notable discount to peers as Q1 earnings loom, but rising costs and tariffs could test its resilience.",
      "url": "https://finnhub.io/api/news?id=a86cc3c3a5ffd984f6a96a10c9806102346e90b237e2f764e53648ad79925614"
    }
  },
  {
    "ts": null,
    "headline": "5 Must-Read Analyst Questions From Global Business Travel’s Q2 Earnings Call",
    "summary": "Global Business Travel’s second quarter results were met with a strong market reaction, as the company delivered revenue in line with Wall Street expectations despite flat year-on-year sales. Management attributed this outcome to a rebound in corporate travel demand in May and June after a weak April, as well as ongoing efficiency gains and cost controls. CEO Paul Abbott highlighted that the company’s focus on operating leverage and efficiency allowed for margin expansion, even as macroeconomic",
    "url": "https://finnhub.io/api/news?id=fce5a095399a49b0d93cc8ecc7f3aa2362b98b7f3b417ed2cea51125b08dd09e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755054292,
      "headline": "5 Must-Read Analyst Questions From Global Business Travel’s Q2 Earnings Call",
      "id": 136328298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Global Business Travel’s second quarter results were met with a strong market reaction, as the company delivered revenue in line with Wall Street expectations despite flat year-on-year sales. Management attributed this outcome to a rebound in corporate travel demand in May and June after a weak April, as well as ongoing efficiency gains and cost controls. CEO Paul Abbott highlighted that the company’s focus on operating leverage and efficiency allowed for margin expansion, even as macroeconomic",
      "url": "https://finnhub.io/api/news?id=fce5a095399a49b0d93cc8ecc7f3aa2362b98b7f3b417ed2cea51125b08dd09e"
    }
  }
]